原发性舍格伦病结局域的识别:OMERACT舍格伦病工作组的一项范围综述
该范围综述系统检索2002年至2023年3月Medline和EMBASE,纳入60项随机对照试验,识别舍格伦病中被评估的结局域并映射至OMERACT 2.1核心领域;结果显示研究设计和结局域存在异质性,将用于OMERACT舍格伦病工作组选择核心域。
要点
- 纳入60项随机对照试验,53%针对整体疾病表现,其余针对单器官或症状。
- 最常评估的结局域包括B细胞活化(60%)、疲劳(57%)、唾液功能(55%)。
- 研究设计和结局域存在异质性,将用于选择核心域和指导未来研究议程。
核心结论
- 该范围综述揭示了舍格伦病在研究设计和结局域上的异质性。
- 该结果将帮助OMERACT舍格伦病工作组选择适用于舍格伦病临床试验的最适核心域,并指导舍格伦病结局测量研究的未来议程。
研究设计与样本
- 系统检索Medline(Pubmed)和EMBASE 2002年至2023年3月,采用手动方法和人工智能软件(BIBOT)自动识别相关摘要。
- 纳入60项随机对照试验,将结局域映射至OMERACT 2.1 Filter建议的核心领域。
主要发现
- 在5,420条参考文献中纳入60项随机对照试验,53%针对整体疾病表现,17%针对干眼,15%针对口干,12%针对疲劳,3%针对肺功能。
- 最常评估的结局域包括B细胞活化(60%)、疲劳(57%)、唾液功能(55%)、感知干燥(整体干燥52%)、疼痛(52%)、泪腺功能(47%)、系统性疾病活动度(45%)和健康相关生活质量(40%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Sjögren's disease (SjD) is a heterogenous disease with a wide range of manifestations, ranging from symptoms of dryness, fatigue, and pain, to systemic involvement. Considerable advances have been made to evaluate systemic activity or patient-reported outcomes, but most of the instruments were not able to assess all domains of this multifaceted disease. The aim of this scoping review was to generate domains that have been assessed in randomized controlled trials, as the first phase of the Outcome Measures in Rheumatology (OMERACT) process of core domain set development. METHODS: We systematically searched Medline (Pubmed) and EMBASE between 2002 and March 2023 to identify all randomized controlled trials assessing relevant domains, using both a manual approach and an artificial intelligence software (BIBOT) that applies natural language processing to automatically identify relevant abstracts. Domains were mapped to core areas, as suggested by the OMERACT 2.1 Filter. RESULTS: Among the 5,420 references, we included 60 randomized controlled trials, focusing either on overall disease manifestations (53%) or on a single organ/symptom: dry eyes (17%), xerostomia (15%), fatigue (12%), or pulmonary function (3%). The most frequently assessed domains were perceived dryness (52% for overall dryness), fatigue (57%), pain (52%), systemic disease activity (45%), lacrimal gland function (47%) and salivary function (55%), B-cell activation (60%), and health-related quality of life (40%). CONCLUSION: Our scoping review highlighted the heterogeneity of SjD, in the study designs and domains. This will inform the OMERACT SjD working group to select the most appropriate core domains to be used in SjD clinical trials and to guide the future agenda for outcome measure research in SjD.
引用
- Nguyen Y, Beydon M, Foulquier N, et al. Identification of outcome domains in primary Sjögren's disease: A scoping review by the OMERACT Sjögren disease working group. Semin Arthritis Rheum. 2024. PMID: 38340608. doi:10.1016/j.semarthrit.2024.152385
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。